UnitedHealth’s second quarter results drew a negative market reaction, as management pointed to higher-than-expected medical costs and operational missteps as central causes. CEO Stephen Hensley described the period as “challenging,” highlighting misjudged pricing assumptions in Medicare Advantage and commercial businesses, as well as a need for fundamental reorientation in some segments. Management acknowledged that rising service intensity, increased provider billing practices, and delayed operational responses contributed to margin pressures. Hensley emphasized, “We’ve made pricing and operational mistakes … they are getting the needed attention.”
Is now the time to buy UNH? Find out in our full research report (it’s free).
UnitedHealth (UNH) Q2 CY2025 Highlights:
- Revenue: $111.6 billion vs analyst estimates of $111.9 billion (12.9% year-on-year growth, in line)
- Adjusted EPS: $4.08 vs analyst expectations of $4.45 (8.3% miss)
- Adjusted EBITDA: $6.23 billion vs analyst estimates of $7.14 billion (5.6% margin, 12.6% miss)
- Management lowered its full-year Adjusted EPS guidance to $16 at the midpoint, a 39% decrease
- Operating Margin: 4.6%, down from 8% in the same quarter last year
- Customers: 54.08 million, down from 54.12 million in the previous quarter
- Market Capitalization: $236.9 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From UnitedHealth’s Q2 Earnings Call
- AJ Rice (UBS) asked how repricing in Medicare Advantage would benefit Optum Health margins. CEO Patrick Conway responded that tighter payer collaboration and benefit reductions should mitigate half of the V28 risk model headwind, with cost reductions and cohort management addressing the rest.
- Justin Lake (Wolfe Research) pressed for clarity on the margin recovery trajectory. CFO John Rex and UnitedHealthcare’s Bobby Hunter explained that pricing resets and benefit changes should move margins toward the new target range in 2026, with improvement continuing into 2027.
- Kevin Fischbeck (Bank of America) inquired about the halted portfolio actions and whether those savings could be recaptured. CEO Stephen Hensley clarified that planned divestitures were paused to focus on existing business performance, with strategic reviews to be revisited later.
- Lisa Gill (JPMorgan) questioned the scale and timing of investments in technology and AI. Hensley and Conway stated that near-term costs would be balanced by long-term growth, particularly from AI-driven solutions in Optum Insight and Financial, with full benefits expected post-2027.
- Sarah James (Cantor Fitzgerald) asked about changes in underwriting and risk review processes. UnitedHealthcare’s Tim Noel and Dan Schumacher described enhanced analytics, deeper actuarial reviews, and greater enterprise-level oversight, aiming for more conservative and adaptive pricing.
Catalysts in Upcoming Quarters
In the coming quarters, our analysts will watch closely for (1) evidence that UnitedHealth’s pricing and benefit adjustments are stabilizing margins across Medicare Advantage, commercial, and Medicaid lines, (2) measurable progress in cost reduction and operational discipline, especially within Optum Health, and (3) successful scaling and market adoption of new AI-powered products in Optum Insight and OptumRx. The outcomes of ongoing regulatory reviews and portfolio optimization efforts will also be key performance indicators.
UnitedHealth currently trades at $262.55, down from $282.12 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.
The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
